Indian healthcare start-up ReaGene Innovations has licensed its two Covid-19 diagnostic tests to US-based company Lay Science.

ReaGene developed the ELISA and FAST FLOW SPOT tests to detect the neutralising activity of samples in response to Covid-19 vaccination.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The body develops neutralising antibodies after being vaccinated against the SARS-CoV-2 virus.

These antibodies help fight the virus and provide protection against infections and disease, but decrease after some time, meaning people may require booster doses.

ReaGene’s ELISA diagnostic test is designed to enable the quantitative evaluation of multiple samples at the same time in a hospital or pathology lab setting.

The FAST FLOW SPOT test is a single-user test that can be used by individuals in their homes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The two diagnostics require an individual’s saliva sample.

ReaGene Innovations scientific co-founder Dr Uday Saxena said: “Collaboration is important as it requires a concerted team effort to fight and win against a virus like Covid-19, the likes of which we have never seen before.

“I am also delighted that with the support of Lays Science, we will be able to globally launch these two tests, which will help us in our fight against Covid-19.”

Under the terms of the license deal, Lay Science will pay for the two patent-pending diagnostics’ development through commercialisation.

In addition, the company will make royalty payments to ReaGene after the launch of the two tests.

Lay Science CEO Dr Satish Chandran said: “These saliva-based ELISA and FAST FLOW SPOT diagnostic tests offer yet another line of defence against the onslaught of rapidly evolving SARS-CoV-2 viral variants.

“These two diagnostic tests are simple and easy-to-use, and this partnership reiterates Lays Sciences’ commitment to fight Covid-19.”

ReaGene Innovations is a start-up incubated at ASPIRE BioNEST, the University of Hyderabad’s Incubation centre.